Since the publication of the first-in-human zirconium-89 (89Zr)-labeled Atezolizumab study in 2018, radiolabeled Atezolizumab and Avelumab, which bind both human and mouse PD-L1, have been explored preclinically in different tumor models (Table 1). Here, CD274 is linked to neoplasm.